%0 Journal Article
%T Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays
%A Clara Lana Yukhtman
%A Elizabeth Marquez-Casas
%A Guy Young
%A Hande Kizilocak
%A Jeanie Lee
%A Jennifer Donkin
%J Archive of "Therapeutic Advances in Hematology".
%D 2019
%R 10.1177/2040620719860025
%X Patients with severe hemophilia A and inhibitors are at risk of bleeding during invasive procedures. The standard of care for preventing perioperative bleeding has been replacement therapy with FVIII concentrates or for patients with high-titer inhibitors, bypassing agents. However, there is no consensus on the appropriate management of surgery in patients receiving the novel agent emicizumab. The aim of this study was to demonstrate a case of a patient on emicizumab undergoing major surgery with bypassing agents with preoperative use of the thrombin generation assay (TGA) and thromboelastography (TEG)
%K bypassing agents
%K emicizumab
%K hemophilia
%K inhibitor
%K thrombin generation test
%K thromboelastography
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598318/